Cutting Drug Prices to Deter Firms From Manufacturing: Biocon Head

Cutting Drug Prices to Deter Firms From Manufacturing: Biocon Head
File photo of Biocon India head Kiran Mazumdar Shaw

Biocon chairperson and managing director Kiran Mazumdar Shaw has raised concerns that the new government's intention to bring down prices of essential drugs by 25-40 per cent could deter manufacturing of such medicines by companies.

While taking charge, Fertiliser and Chemicals Minister Ananth Kumar had said that he would talk to pharmaceutical companies and try to bring down prices of essential drugs by 25-40 per cent.

"Minister Ananth Kumar's mandate to further reduce drug prices can potentially deter quality drug makers from manufacturing essential drugs," Ms Shaw said on the micro blogging site Twitter.

She further said the minister "must factor cost of quality systems else you will get poor quality of cheap drugs".

She stressed that unless the pharma sector is spared from multiple and conflicting regulations, it will not realise global leadership potential.

"Minister Ananth Kumar should make right to healthcare a reality thru (sic) large scale drug procurement of essential drugs not thru (sic) forced rebate," she added.

Pharmaceutical industry bodies such as IPA (Indian Pharmaceutical Alliance), IDMA (Indian Drug Manufacturers' Association), however, declined to comment on the issue.

"It is too early to comment," they added.

Mr Kumar, who is also responsible for the Department of Pharmaceuticals, had said the government would talk to global pharmaceutical firms to bring down the cost of drugs.

"... as far as branded medicines of multinational pharmaceutical companies are concerned, we will talk to all of them and try to bring down prices of essential drugs for poor by 25-40 per cent," he had said.

Last year, the government had notified the new drug pricing policy, bringing 348 formulations listed in the National List of Essential Medicines (NLEM) under the price control regime thereby reducing their prices.

In the earlier policy, the government through the National Pharmaceutical Pricing Authority (NPPA) controlled prices of 74 bulk drugs and their formulations.

Unlock this article for free
Sign up to access exclusive stories, fewer ads, and a personalised experience.
Set as Trusted Source
on Google Search